November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its ...
Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...
November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...
CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...
Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...
A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...
A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with intermediate-risk ...
Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...
DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...
The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...
In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...
A post hoc analysis of the SIRONA trial investigated how sirolimus-coated balloon angioplasty compares to various paclitaxel dr ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback